Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01245556 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

A Phase 1 study of Melanoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
2
Study locations

NCT01245556 is a Phase 1 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 8 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01245556, a Phase 1 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when administered in combination with ipilimumab.

Conditions Studied

Melanoma

Interventions

  • DRUG Ipilimumab
  • DRUG BMS-908662

Study Locations (2)

Florida

  • H. Lee Moffitt Cancer Center & Research Institute - Tampa

New York

  • Jedd D. Wolchok, Md,Phd - New York

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2011-01
Est. Completion 2012-11
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01245556

The ClinicalTrials.gov registry entry for NCT01245556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab is the first listed.

NCT01245556 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, New York.

Frequently Asked Questions

What is clinical trial NCT01245556 about?

NCT01245556 is a clinical study titled "Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma". The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when administered in combination with ipilimumab.

What is the current status of trial NCT01245556?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2011-01. Estimated completion is 2012-11.

What conditions does trial NCT01245556 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT01245556?

The interventions under investigation include: Ipilimumab (DRUG), BMS-908662 (DRUG).

Who is sponsoring clinical trial NCT01245556?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01245556 being conducted?

This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.